Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics

Short title: Seroconversion and virological characteristics

Noriko Misawa,¹ Akihiro Matsumoto,¹ Eiji Tanaka,¹ Akinori Rokuhara,¹ Kaname Yoshizawa,¹ Takeji Umemura,¹ Noboru Maki,² Tatsuji Kimura,² and Kendo Kiyosawa¹,³

¹Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan
²Advanced Life Science Institute, Inc., Wako, Japan
³Shinshu University Graduate School of Medicine, Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, Matsumoto, Japan

Corresponding author: Eiji Tanaka, M.D., Second Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan
Phone: + 81-263-37-2634, Fax: + 81-263-32-9412
E-mail: etanaka@hsp.md.shinshu-u.ac.jp
Summary

The characteristic differences between patients with and without loss of hepatitis B virus (HBV) DNA after achieving hepatitis B e antigen seroconversion were analyzed by comparing changes in HBV DNA and HBV core-related antigen levels during a period from 3 years before to 3 years after the seroconversion. Of the 24 seroconverters, 6 (inactive replication group) showed continuous loss of HBV DNA in serum after the seroconversion and the remaining 18 did not (active replication group). The HBV DNA level was similar between the two groups, while the HBV core-related antigen level was significantly lower in the active replication group than in the inactive replication group before the seroconversion. The levels of both HBV DNA and HBV core-related antigen decreased remarkably around the time of seroconversion in the inactive replication group, while these levels did not change or decreased slightly in the active replication group. After the seroconversion, the HBV DNA level was significantly higher in the active replication group than in the inactive replication group, while the HBV core-related antigen level was similarly low between the two groups. Because the serum level of HBV core-related antigen mainly reflects that of HBe antigen, the low level of HBV core-related antigen seen after seroconversion in both groups might have contributed to the occurrence of seroconversion. The precore and core promoter mutations which cause diminished excretion of hepatitis B e antigen were significantly more frequent in the active replication group than in the inactive replication group. It was therefore considered that the seroconversion was caused mainly by a decrease in viral replication in the inactive replication group, and mainly by a decrease in HBe antigen production in the active replication group.

Keywords: HBV DNA, seroconversion, HBV core-related antigen, precore mutation, core promoter mutation
Introduction

A total of 350 million people worldwide are estimated to be carriers of hepatitis B virus (HBV) [Maynard, 1990; Maddrey, 2000]. HBV is important as a causative agent for liver diseases such as chronic hepatitis and hepatocellular carcinoma, especially in Asian countries [Lee, 1997]. In the natural history of chronic HBV infection, seroconversion from hepatitis B e (HBe) antigen to its antibody (anti-HBe) is usually accompanied by a decrease in HBV replication and remission of hepatitis [Hoofnagle et al., 1981; Liaw et al., 1983; Realdi et al., 1980]. Thus, HBe antigen seroconversion is a favorable sign for patients with chronic hepatitis B. However, there are some patients who continue to have elevated HBV DNA levels in the serum and active liver disease after the seroconversion [Bonino et al., 1986; Hsu et al., 2002].

Although the detailed mechanisms of HBe antigen seroconversion have not been fully clarified, several mutations in the HBV genome have been reported to be associated with the phenomenon. When the precore (pre-C) and core genes in the HBV genome are transcribed and translated in tandem, HBe antigen is produced and secreted into circulation [Bruss et al., 1988; Garcia et al., 1988]. The G to A mutation at nucleotide (nt) 1896 in the pre-C region (G1896A), which converts codon 28 for tryptophan to a stop codon, is associated with the loss of HBe antigen [Carman et al., 1989; Okamoto et al., 1990]. The double mutation (A1762T and G1764A) in the core promoter (CP) has been shown to reduce the synthesis of HBe antigen by suppressing the transcription of precore mRNA [Okamoto et al., 1994; Buckword et al., 1996; Takahashi et al., 1995]. Convincing lines of evidence have indicated a close association of HBe antigen seroconversion with the appearance of precore and core promoter mutations [Okamoto et al., 1994; Buckword et al., 1996; Takahashi et al.,
A chemiluminescence enzyme immunoassay (CLEIA) was previously developed by our research team for the detection of HBV core-related antigen [Kimura et al., 2002; Rokuhara et al., 2003]. The HBV core-related antigen is expressed on HBe and core (HBc) antigens; both proteins are transcribed from the precore/core gene and their first 149 amino acids are identical. The HBVcrAg CLEIA measures the serum levels of HBe and HBc antigens simultaneously, using monoclonal antibodies which recognize common epitopes of these two denatured antigens. However, the amount of HBV core-related antigen mainly reflects that of HBe antigen, because the concentration of HBe antigen in serum is much higher than that of HBc antigen [Kimura T. et al, 2002]. In the present study, we analyzed the characteristic differences that may exist between patients with and without HBV DNA in serum after HBe antigen seroconversion by comparing chronological changes of HBV DNA and HBV core-related antigen as well as by testing HBV genome mutations associated with the seroconversion.

Material and Methods

Patients

The present study is a retrospective one using stored sera from Japanese patients with chronic hepatitis B seen in Shinshu University Hospital. The clinical database was reviewed to identify all patients who had been followed from January 1985 to June 2001 and also showed seroconversion from HBe antigen to anti-HBe during the follow-up period. A total of 24 patients were recruited into the present study. The 24 patients consisted of 17 men and 7 women with a median age of 39 years.
Seroconversion of HBe antigen was defined as disappearance of HBe antigen accompanied by the development of anti-HBe on at least two consecutive visits. All 24 patients met the following three criteria: (1) follow-up was performed for at least 3 years before and after the seroconversion; (2) chronic hepatitis without liver cirrhosis was confirmed by histological examination; and (3) serum samples were available for testing every 6 months during the follow-up period. Of the 24 patients, 12 patients received interferon administration of at most 4 weeks and none received nucleotide analogues such as lamivudine, adefovir, or entecavir during the follow-up period.

Serum concentrations of HBV DNA and HBV core-related antigen were determined every 6 months during the follow-up period, which ran from 3 years before to 3 years after the seroconversion. The presence or absence of the pre-C mutation of A1896 and the double mutation in the CP (T1762/A1764) was determined every year during the follow-up period. The serum samples had been stored at -20°C or below until tested. Written informed consent was obtained from each patient.

**Serological markers for HBV**

Conventional HBV markers, including HBe antigen and anti-HBe, were tested using CLEIA kits (Fuji Rebio, Tokyo, Japan). Six major genotypes (A-F) of HBV were determined using the method reported by Mizokami et al. [1999], in which the surface gene sequence amplified by PCR was analyzed by restriction fragment length polymorphism.

The Pre-C and CP mutations were determined on nucleic acids extracted from 100 µL of serum with a DNA/RNA extraction kit (Smitest EX-R and D; Genome Science Laboratories Co., Ltd., Tokyo, Japan). The stop codon mutation in the Pre-C region (A1896) was detected with an enzyme-linked mini-sequence assay kit.
(Smitest; Genome Science Laboratories). In principle, G1896 in the wild-type HBV and A1896 in the mutants were determined by mini-sequence reactions using labeled nucleotides that are complementary to either the wild-type or mutant. The results were expressed as a percent mutation rate according to the definition by Aritomi et al. [1998]. The sample was judged positive for the pre-C mutation when the mutation rate exceeded 50% in the present study, because the mutation rate steadily increase to 100% afterward once it exceed the rate of 50% [Yamaura et al., 2003]. The double mutation in the CP was detected using an HBV core promoter detection kit (Smitest; Genome Science Laboratories) [Aritomi et al., 1998]. This kit detects T1762/G1764 or A1762/T1764 by a polymerase chain reaction (PCR) with primers specific for either the wild-type or mutant. The results were recorded in three categories, i.e., wild, mixed, and mutant types. In the present study, the sample was considered positive for the CP mutation when the results were in the mutant type category. The detection limits of the pre-C and the CP mutation kits are both 1,000 copies/mL according to the manufacturer. The pre-C mutation could be determined in 136 (99%) of 137 samples which had HBV DNA levels higher than 1,000 copies/mL and in 30 (97%) of 31 samples which had levels lower than 1,000 copies/mL. Similarly, the CP mutation could be determined in 136 (99%) of 137 samples and in 28 (90%) of 31 samples.

The serum concentration of HBV DNA was determined using an Amplicor HBV monitor kit (Roche, Tokyo, Japan) which had a quantitative range of 2.6 to 7.6 log copies/mL [Kessler et al., 1998]. Sera containing over 7.0 log copies/mL HBV DNA were diluted 10- or 100-fold in normal human serum and measured again to obtain the end titer.

The serum concentration of HBV core-related antigen was measured using the CLEIA reported previously [Kimura et al., 2002; Rokuhara et al., 2003]. In
summary, 100 µL serum was mixed with 50 µL pretreatment solution containing 15% sodium dodecylsulfate and 2% Tween 60. After incubation at 70°C for 30 min, 50 µL pretreated serum was added to a well coated with monoclonal antibodies against denatured HBc and HBe antigens (HB44, HB61, and HB114) and filled with 100 µL assay buffer. The mixture was incubated for 2 h at room temperature and the wells were washed with buffer. Alkaline phosphatase-labeled monoclonal antibodies against denatured HBc and HBe antigens (HB91 and HB110) were added to the well, and incubated for 1 h at room temperature. After washing, CDP-Star with Emerald II (Applied Biosystems, Bedford, MA) was added and the plate was incubated for 20 min at room temperature. The relative chemiluminescence intensity was measured, and the HBV core-related antigen concentration was read by comparison to a standard curve generated using recombinant pro-HBe antigen (amino acids –10 to 183 of the precore/core gene product). The HBV core-related antigen concentration was expressed as units/mL (U/mL) and the immunoreactivity of recombinant pro-HBe antigen at 10 fg/mL was defined as 1 U/mL. In the present study, the cutoff value was set tentatively at 3.0 log U/mL. Sera containing over 7.0 log U/mL HBV core-related antigen were diluted 10- or 100-fold in normal human serum and measured again to obtain the end titer.

**Statistical Analyses**

The Mann-Whitney test was used to analyze continuous variables. The Fisher’s exact test was used in the analysis of categorical data. The Manzel Haentel chi-square test was used to evaluate positive rates for the pre-C and CP mutations. The Wilcoxon test was used to analyze the change in the level of HBV DNA and HBV core-related antigen. *P* values less than 0.05 were considered significant. Statistical
analyses were performed using an SPSS 5.0 statistical software package (SPSS Inc., Chicago, IL).

**Results**

**Grouping of seroconverters according to HBV DNA outcome**

The 24 seroconverters enrolled in the present study were classified into two groups according to changes in serum levels of HBV DNA. The HBV DNA level decreased substantially around the time of the seroconversion and then became continuously undetectable in one group (inactive replication group), and the level decreased slightly and did not become continuously undetectable even after the seroconversion in another group (active replication group). In the present study, the former group of patients were defined as those whose HBV DNA levels were lower than 2.6 log copies/mL at each of the time points of 1.5, 2, 2.5, and 3 years after the seroconversion, and the latter group of patients were defined as those whose HBV DNA levels were not. Of the 24 seroconverters, 6 belonged to the inactive replication group and the remaining 18 belonged to the active replication group.

The clinical backgrounds of the active and inactive replication groups are compared in Table 1. The median age, gender ratio, and history of interferon therapy did not differ between the two groups. All patients were infected with genotype C HBV. Normalization of serum alanine aminotransferase (ALT) after seroconversion was considered to have occurred in cases in which ALT was normal at each of the time points of 2, 2.5, and 3 years after the seroconversion in the present study. The normalization of ALT was more frequent in the inactive replication group than in the active replication group, but the difference was not statistically significant.
Changes in HBV DNA and HBV core-related antigen concentration

Changes in the serum level of HBV DNA are compared between the active and inactive replication groups in Figure 1-A. At the start-point of the follow-up, the level was distributed within a similarly high range in both groups. In the inactive replication group, the median concentration decreased around the time of seroconversion and became continuously undetectable thereafter. In the active replication group, on the other hand, the median concentration tended to decrease around the time of seroconversion, but was not undetectable even at 3 years after seroconversion. The median HBV DNA level in the active replication group was significantly higher than that in the inactive replication group at 1.5 years after the seroconversion and each of the subsequent time points.

Changes in the serum concentration of HBV core-related antigen are compared between the active and inactive replication groups in Figure 1-B. The concentration of HBV core-related antigen was significantly higher in the inactive replication group than in the active replication group at the start of the follow-up and at 1.5 and 2 years before the seroconversion point. The median concentration of HBV core-related antigen in the inactive replication group appeared to decrease around the time of seroconversion and reached a level comparable to that in the active replication group. The median HBV core-related antigen level was similar between the inactive and active replication groups at all time points after the seroconversion, and it decreased slowly with time in both groups.

Changes in the log ratio of HBV core-related antigen/HBV DNA concentrations are compared between the inactive and active replication groups in Figure 2. The values of HBV core-related antigen and HBV DNA were substituted by their corresponding detection limit values when they were under the detection limit.
The log ratio was similar between the two groups at points before the seroconversion. The log ratio decreased after the seroconversion in the active replication group, but did not change in the inactive replication group. The log ratio of HBV core-related antigen/HBV DNA was significantly lower in the active replication group than in the inactive replication group at all post-seroconversion time points except 1 year.

**Comparison of pre-C and CP mutations**

The positive rates for the pre-C and CP mutations at the time points before and after the seroconversion are compared between the inactive and active replication groups in Figure 3. The pre-C mutation did not appear during the follow-up period in the inactive replication group. On the other hand, the positive rate for the pre-C mutation was around 30% before the seroconversion, and then increased to around 60% after the seroconversion in the active replication group. The difference in the positive rate was significant at the time points of 2 and 3 years after the seroconversion. The positive rate for the CP mutation was less than 40% in the inactive replication group during the follow-up period except at the last time point, while it was over 60% in the active replication group throughout the follow-up period. The difference in the positive rate was statistically significant at the time points of 2 and 3 years before the seroconversion and at 1 and 2 years after it.

**Discussion**

We tentatively divided seroconverters into two groups according to their levels of serum HBV DNA in the present study. It has been reported that older age and female gender are factors predicting occurrence of HBe antigen seroconversion in patients with chronic hepatitis B [Lok et al., 1987; McMahon et al., 2001; Alward et al., 1985]. On the
other hand, in the present study, median age and gender distribution were similar between the inactive and active replication groups. A history of interferon treatment was recorded in half of the patients enrolled. The treatment history did not seem to be associated with the loss of HBV DNA after seroconversion, because the history was similarly distributed between the two groups and the duration of interferon therapy was as short as 4 weeks at most. Although the difference was not statistically significant, patients in the inactive replication group tended to show continuous normalization of ALT. Further, none of the 6 patients in the inactive replication group developed end stage liver diseases such as cirrhosis and hepatocellular carcinoma after the follow-up period, while 4 of the 18 patients in the active replication group developed them (data not shown). High viral load, which is usually associated with active hepatitis, has been reported to be a risk factor for development of hepatocellular carcinoma even in patients with chronic hepatitis B who achieved HBe antigen seroconversion [Ikeda et al., 2003; Ohata et al., 2004]. We could not compare long-term prognosis between patients in the inactive and active replication groups in the present study. However, patients in the active replication group tended to show active hepatitis after the seroconversion and to develop end stage liver diseases. Thus, further analysis of patients whose active viral replication continues after the seroconversion would be of clinical significance.

Analysis of the changes in HBV DNA and HBV core-related antigen revealed a clear contrast between the two. Namely, the HBV DNA level was similar between the two groups, while HBV core-related antigen was significantly lower in the active replication group than in the inactive replication group before seroconversion. The levels of both HBV DNA and HBV core-related antigen decreased remarkably around the time of seroconversion in the inactive replication group, while these levels did not change or decreased slightly in the active replication group. After seroconversion, the
HBV DNA level was significantly higher in the active replication group than in the inactive replication group, while the HBV core-related antigen level was similar between the two groups. Because the discrepancy in the log ratio of HBV core-related antigen/ HBV DNA between the two groups first appeared at the time of seroconversion and continued thereafter, the difference between the HBV DNA and HBV core-related antigen changes was suggested to be closely associated with the seroconversion. The results obtained in the present study indicate that the mechanism of seroconversion was different between the two groups.

Because the serum level of HBV core-related antigen mainly reflects that of HBe antigen [Kimura et al., 2002], the low level of HBV core-related antigen seen after seroconversion in both the inactive and active replication groups might have contributed to the occurrence of seroconversion. The pre-C and CP mutations, which were associated with the seroconversion, were frequent in the active replication group and rare in the inactive replication group, at least at around the time of seroconversion. The decrease of HBV core-related antigen excretion seen after seroconversion was thought to have been caused mainly by the decrease of viral replication in the inactive replication group, because viral replication did not resume in this group. On the other hand, the decrease of HBV core-related antigen was thought to have been caused mainly by the appearance of pre-C and/or CP mutations, because active viral replication continued in this group. These results suggested that the two groups had different mechanisms of seroconversion.

It has been reported that the frequency of the pre-C and the CP mutations differs among HBV genotypes. Orito et al. reported that the CP mutation was significantly associated with genotype C [Orito et al., 2001]. Yamaura et al. [2003] reported that the CP mutation was already commonly seen several years before the
seroconversion in patients with genotype C. These results are consistent with the present finding that the majority of patients in the active replication group had the CP mutation from the start of follow-up. The fact that patients in the active replication group had a lower level of HBV core-related antigen before the seroconversion may be attributable to the frequent CP mutation seen in this group.

In conclusion, the present study showed that there were different mechanisms of HBe antigen seroconversion between patients in whom HBV viremia continued after the seroconversion and those in whom it did not. Measurement of HBV core-related antigen in addition to HBV DNA was suggested to be useful in analyzing specific conditions of chronic hepatitis B.

Acknowledgments

We thank Ms. Toyo Amaki and Ms. Asami Yamazaki for their technical assistance. This research was supported in part by a Grant-in Aid from the Ministry of Health, Labour and Welfare of Japan (no. 1640013-41).
References


Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.


Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. 1990. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the


Table 1. Comparison of clinical backgrounds between the inactive and active replication groups.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Inactive replication group n=6</th>
<th>Active replication group n=18</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at seroconversion (yr) a</td>
<td>37 (23-65)</td>
<td>39 (17-64)</td>
<td>&gt; 0.2 d</td>
</tr>
<tr>
<td>Gender (M:F)</td>
<td>4:2</td>
<td>13:5</td>
<td>&gt; 0.2 e</td>
</tr>
<tr>
<td>Genotype C b</td>
<td>6 (100%)</td>
<td>18 (100%)</td>
<td>&gt; 0.2 e</td>
</tr>
<tr>
<td>History of interferon therapy b</td>
<td>3 (50%)</td>
<td>9 (50%)</td>
<td>&gt; 0.2 e</td>
</tr>
<tr>
<td>ALT normalization c</td>
<td>4 (67%)</td>
<td>5 (28%)</td>
<td>0.150 e</td>
</tr>
</tbody>
</table>

a Data are expressed as the median (range).

b Data are expressed as a positive number (percent).

c Normalization of serum ALT level after seroconversion (the ALT value was within the normal range at each of the time points of 2, 2.5, and 3 years after the seroconversion).

d Mann-Whitney test

e Fisher’s exact test
**Figure Legends**

**Figure 1.** Comparison of changes in HBV DNA (A) and HBV core-related antigen (B) levels between the inactive and active replication groups. Data are shown as the median ± 25% ranges. The broken lines indicate the detection limits of the HBV DNA and HBV core-related antigen assays, respectively. Open circles indicate inactive replication group and closed circles indicate active replication group.

* P< 0.05 between the inactive and active replication groups.

**Figure 2.** Comparison of changes in the log ratio of HBV core-related antigen/HBV DNA levels between the inactive and active replication groups. Data are shown as the median ± 25% ranges. Open circles indicate inactive replication group and closed circles indicate active replication group.

* P< 0.05 between the inactive and active replication groups.

**Figure 3.** Comparison of positive rates for the pre-C (A) and CP (B) mutations between the inactive and active replication groups. Open bars indicate inactive replication group and closed bars indicate active replication group.

Number of patients in the inactive replication group is 6 at each time point except the followings: point 0 year (n=5) in A, and points 0 year (n=5), 1 year (n=5), and 2 years (n=5) in B. Number of patients in the active replication group is 18 at each time point except the followings: point 0 year (n=17) in A and point 0 year (n=17) in B.

* P< 0.05 between the inactive and active replication groups.
Fig. 2

Log ratio of HBV core-related antigen / HBV DNA concentrations

Years from seroconversion

* * *
Fig. 3

A

B

Pre-C mutation positive (%)

CP mutation positive (%)

Years from seroconversion

Years from seroconversion

* * *